Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero-Torres

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Breast Cancer Research and Treatment|June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPTPaolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Breast Cancer Research and Treatment|June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPTPaolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 10